Skip to main content
Clinical Trials/NCT05739253
NCT05739253
Recruiting
Not Applicable

Changes of Ascending Aortic Diameter in Patients Undergoing Transcatheter Aortic Valve Replacement

China National Center for Cardiovascular Diseases1 site in 1 country480 target enrollmentMarch 22, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aortic Stenosis
Sponsor
China National Center for Cardiovascular Diseases
Enrollment
480
Locations
1
Primary Endpoint
Rate of ascending aortic dilatation
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this observational study is to assess the changes of ascending aortic diameter in patients undergoing transcatheter aortic valve replacement. The main questions it aims to answer are:

  1. whether the ascending aortic diameter increases or remains stable after transcatheter aortic valve replacement, especially in patients with preoperative ascending aortic dilatation;
  2. the determinants of postoperative ascending aortic dilatation.

Detailed Description

Ascending aortic (AA) dilatation occurs frequently in patients with aortic stenosis (AS). For patients who are candidates for transcatheter aortic valve replacement (TAVR), simultaneous repair of a dilatated AA is technically difficult. As the indications for TAVR have extended to low-risk patients and patients with bicuspid aortic valve , AA dilatation should be considered as a new criterion to refine risk stratification in patients undergoing TAVR. In this observational study, we aim to evaluate the changes of AA diameters and identify the determinants post-TAVR AA dilatation.

Registry
clinicaltrials.gov
Start Date
March 22, 2022
End Date
March 21, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
China National Center for Cardiovascular Diseases
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Severe aortic stenosis defined as an aortic valve area of 1cm2 or less or an indexed aortic valve area of 0.6cm2/m2 or less;
  • Presence of clinical symptoms defined as a New York Heart Association functional class of 2 or more;
  • High risk of surgical aortic valve replacement;
  • Suitability for a transfemoral vascular access.

Exclusion Criteria

  • Dominant aortic regurgitation;
  • History of surgical or transcatheter aortic valve replacement;
  • History of aortic surgery;
  • Connective tissue disorders.

Outcomes

Primary Outcomes

Rate of ascending aortic dilatation

Time Frame: 1-year and 2-year

The change of AA diameters (before the procedure and at the latest follow-up) divided by the follow-up period.

Secondary Outcomes

  • Rate of all-cause mortality(1-year and 2-year)
  • Rate of adverse aortic events(1-year and 2-year)

Study Sites (1)

Loading locations...

Similar Trials